Jun 29,2023

ABBOTT HOSTS CONFERENCE CALL FOR SECOND-QUARTER EARNINGS

Abbott will announce its second-quarter 2023 financial results on Thursday, July 20, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 24,2023

Minutia, Oregon Health & Sciences University and Go Pen Win First-Ever American Diabetes Association Innovation Challenge

The American Diabetes Association (ADA) Innovation Challenge at the 83rd Scientific Sessions awarded Minutia, Oregon Health & Sciences University, and Go Pen for their transformative solutions to diabetes challenges. The competition aimed to connect innovators and startups with potential funders and showcased six business concepts. The judges represented the three potential funders: Helmsley Charitable Trust, Swiss Diabetes Venture Fund, and Startup Health. GO-Pen, one of the winners, is presented as the only insulin pen where people with diabetes can buy insulin in vials and fill their own reservoirs for use with an insulin pen. The other finalists include Neurovalens, Devyn and Angel Watch Company.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

Beta Bionics Announces FDA Clearance for the use of a Prefilled Insulin Cartridge with the iLet Bionic Pancreas

Beta Bionics has received FDA clearance for compatibility with the Fiasp® Pumpcart® (insulin aspart) prefilled insulin cartridge with the iLet Bionic Pancreas. The iLet is the first and only automated insulin-delivery system that does not require carb counting and fully automates 100% of all user insulin doses – and will provide users the choice of three insulins – Novolog®, Humalog® and Fiasp® Pumpcart®.

REGULATORY FDA

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

ABBOTT'S FREESTYLE LIBRE 2 RECEIVES NATIONAL REIMBURSEMENT IN FRANCE FOR ALL PEOPLE WITH DIABETES WHO USE INSULIN

Abbott's FreeStyle Libre 2 system has received national reimbursement in France for all individuals who use basal insulin as part of their diabetes management. FreeStyle Libre 2 was previously covered only for people with Type 1 and Type 2 diabetes who require intensive insulin therapy. France is the first European country to provide national reimbursement for basal insulin users, following similar expansions in Japan and the U.S. Medicare system.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

Insulet Celebrates One Year of Omnipod® 5 at the American Diabetes Association 83rd Scientific Sessions

Insulet Corporation is celebrating one year of its flagship product, Omnipod 5, at the American Diabetes Association (ADA) 83rd Scientific Sessions. The company will present real-world evidence of improved outcomes using Omnipod 5 and discuss future innovations, including an iOS app and integration with Abbott's FreeStyle Libre 2 sensor. Clinical presentations and poster presentations highlighting the benefits of Omnipod systems will also be shared at the conference.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

Insulin Pump Market Size to Reach USD 14.99 Billion by 2032 at 15.50% CAGR

The global insulin pump market is expected to reach USD 14.99 billion by 2032, growing at a CAGR of 15.50%, by the publisher. Factors driving market growth include increasing demand for handheld insulin dispensers, rising incidence of diabetes, and advancements in technology, such as AI-enabled pumps. The market is also propelled by the advantages of insulin pumps over other devices, growing awareness and adoption, and research and development efforts. Factors like the aging population, obesity, and unhealthy lifestyles contribute to the rise in diabetes cases and the need for innovative management strategies.

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

Nemaura Medical to Participate at the Collision Conference in Toronto June 26-29, 2023

Nemaura Medical will participate in the Collision Conference, in Toronto June 26-29, 2023, showcasing its non-invasive wearable sensors and personalized weight reduction programs for diabetes management. The conference will feature live demonstrations and meetings with investors and media

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More

Dexcom has unveiled plans to launch a new product with a 15-day wear period and include a cash-pay option, together with a new software experience tailored for people not on insulin in the U.S. in 2024. Dexcom's CGM technology is expanding globally, with availability in 14 countries and its recent entry into the Latin American market. Additionally, the company reported that the coverage for Dexcom CGM by private payers in the U.S. is increasing, following Medicare's lead. Projections suggest that millions of people with a history of problematic hypoglycemia are now covered for Dexcom CGM through Medicare.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

South Korea approves first local CGM device

The South Korean Ministry of Food and Drug Safety has approved the first locally-developed continuous glucose monitoring (CGM) device, the CareSens Air, developed by i-SENS. The device is small, light, and offers reliable readings. i-SENS plans to launch it in Q3 2023 and seeks CE clearance for the European market by H1 2024. This approval marks the fourth CGM device approved by the South Korean government, following foreign products by Medtronic, Abbott, and Dexcom.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

The Global Continuous Glucose Monitoring Devices Market is Projected to reach USD 11.2 billion by 2030, with a CAGR of 4.4% from 2023 to 2030

The global continuous glucose monitoring devices market is projected to reach USD 11.2 billion by 2030, with a CAGR of 4.4% from 2023 to 2030. Factors driving market growth include the increasing incidence of diabetes and the introduction of technologically advanced diabetes care devices. These devices enable real-time monitoring of glucose levels and are integrated with apps and software for better management of diabetes. The market is expected to benefit from government initiatives and rising healthcare expenditure on diabetic care.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES